JLK has launched its AI-powered MRI stroke analysis software, JLK-DWI, in Japan after securing regulatory approval, the company said Tuesday.
The tool analyzes diffusion-weighted MRI scans to detect hyper-intensity areas—key markers of acute ischemic stroke—and calculates lesion volume.
JLK-DWI joins four other stroke-related AI modules already approved in Japan: CT perfusion (JLK-CTP), MR perfusion (JLK-PWI), non-contrast CT (JLK-NCCT), and most recently, JLK-FLAIR, which analyzes high-signal intensity areas in MRI FLAIR (fluid-attenuated inversion recovery) scans.
The company plans to complete approvals for the remaining modules to offer a full-stack stroke AI solution.
JLK cited strong demand from Japan’s aging population and positive clinical feedback during local testing. Professor Manabu Inoue of Japan’s National Cerebral and Cardiovascular Center recently highlighted the software at STROKE 2025 JAPAN and will lead a Korea-Japan webinar on its clinical use this month.
To support the rollout, JLK said it will strengthen its local supply chain by partnering with hospitals and medical device distributors.
Related articles
- JLK snags 4th Japan nod for stroke AI, targets underserved hospitals
- JLK notches 7th FDA nod for AI stroke detection as 8 more line up in US push
- JLK secures FDA clearance for AI-powered medical imaging platform
- JLK wins Japan’s approval for AI stroke diagnosis tool
- JLK to present AI-based diagnostics at international stroke meet ISC 2025
- JLK wins FDA approval for intracranial hemorrhage detecting AI solution
- JLK secures FDA 510(k) clearance for stroke solution
- JLK secures 2nd innovative stroke AI nod as Korea’s 80-day fast-track policy kicks in
- HLB forms Korea-Japan alliance to pilot predictive elder-care tools
- JLK teams with Marubeni’s Clairvo to roll out stroke AI in Japan
- JLK secures Japan PMDA approval for brain MRI AI solution